December 17, 2014
Regulatory authorities in Bulgaria approved patient enrollment for the second cohort of a phase 2 clinical study in glaucoma, Can-Fite BioPharma and OphthaliX announced in a press release.
In the first cohort study, patients were treated with 1 mg CF101, an A3 adenosine receptor agonist that acts as a neuroprotective agent and prevents apoptosis of retinal ganglion cells, or placebo. Masked results showed that CF101 had a favorable safety profile and was well-tolerated, the release said. A previous ophthalmic study showed CF101 lowered IOP.